Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

NCT05901584 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Immunotherapy
Second-line Treatment

Interventions

DRUG: Cadonilimab

Sponsor

Second Affiliated Hospital of Zunyi Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]